654671-77-9 Usage
Description
Sitagliptin phosphate monohydrate is a white crystalline compound that functions as a dipeptidyl peptidase-IV (DPPIV) inhibitor. It is a pharmaceutical agent used to manage blood glucose levels in patients with type 2 diabetes by enhancing the levels of insulin and reducing the production of glucagon.
Uses
Used in Pharmaceutical Industry:
Sitagliptin phosphate monohydrate is used as an antimuscarinic agent for the treatment of type 2 diabetes. It helps in controlling blood sugar levels by inhibiting the DPP-IV enzyme, which in turn increases the levels of insulin and decreases the production of glucagon, leading to better glucose management in the body.
Used in Diabetes Management:
Sitagliptin phosphate monohydrate is used as an oral antidiabetic drug for managing type 2 diabetes. It aids in improving glycemic control by modulating the actions of incretin hormones, which are responsible for stimulating insulin secretion and suppressing glucagon release, thus maintaining a balanced blood glucose level.
Biological Activity
sitagliptin phosphate monohydrate is the phosphate salt of its active component, sitagliptin, with one molecule of water. sitagliptin is a potent inhibitor of dipeptidyl peptidase 4 (dpp-4), an enzyme catalyzing the cleavage of peptides with an n-terminal alanine or proline amino acid residue, that selectively inhibits dpp-4 with 50% inhibition concentration ic50 value of 18 nm and shows no affinity towards other ddp enzymes (such as ddp-8 and ddp-9). the inhibition of dpp4 by sitagliptin has been found to be mediated by increasing levels of two dpp-4 substrates, including glucagon-like peptide-1 (glp-1) and gastric inhibitory polypeptide (gip). sitagliptin is currently being investigated in the treatment of type ii diabetes.gallwitz b. review of sitagliptin phosphate: a novel treatment for type 2 diabetes. vasc health risk manag. 2007;3(2):203-10.
Check Digit Verification of cas no
The CAS Registry Mumber 654671-77-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,5,4,6,7 and 1 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 654671-77:
(8*6)+(7*5)+(6*4)+(5*6)+(4*7)+(3*1)+(2*7)+(1*7)=189
189 % 10 = 9
So 654671-77-9 is a valid CAS Registry Number.
InChI:InChI=1/C16H15F6N5O.H3O4P.H2O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4;/h4,6,9H,1-3,5,7,23H2;(H3,1,2,3,4);1H2/t9-;;/m1../s1
654671-77-9Relevant articles and documents
BOC-(R)-3-amino-4-(2,4,5-trifluorophenyl)butyric acid condensation impurity and preparation method thereof
-
, (2019/07/04)
The invention provides a sitagliptin phosphate important intermediate BOC-(R)-3-amino-4-(2,4,5-trifluorophenyl)butyric acid condensation impurity and a preparation method and preparation thereof. TheBOC-(R)-3-amino-4-(2,4,5-trifluorophenyl)butyric acid condensation impurity and the preparation method thereof have important significance for the following industrial production of bulk drugs.
SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF
-
, (2013/06/28)
The present invention relates to an improved process for preparation of Sitagliptin or pharmaceutically acceptable salts thereof. The present invention further relates to novel polymorphs of Sitagliptin salts and process for preparation thereof.
AMORPHOUS FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
-
Page/Page column 14, (2008/06/13)
The present invention relates to a novel amorphous form of the dihydrogenphosphate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-a mine as well as a process for its preparation, pharmaceutical compositions containing this novel form, and methods of use of the novel form and pharmaceutical compositions for the treatment of diabetes, obesity, and high blood pressure.